Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
A Phase II study was done on a treatment called CART-ddBCMA. This treatment is for people with a type of cancer called multiple myeloma that came back after treatment or didn't respond to treatment. CART-ddBCMA is a special therapy using cells that can recognize and attack the cancer cells. The study looked at how well this treatment worked for these patients.
A Phase II study was done on a treatment called CART-ddBCMA. This treatment is for people with a type of cancer called multiple myeloma that came back after treatment or didn't respond to treatment. CART-ddBCMA is a special therapy using cells that can recognize and attack the cancer cells. The study looked at how well this treatment worked for these patients.
Third Opinion AI Generated Synopsis
Trial Summary
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
